1
Karl Heinz Altmann, Rene Imwinkelried, Albert Eschenmoser: Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates. Novartis Corporation, Gregory D Ferraro, December 23, 1997: US05700920 (246 worldwide citation)

Compounds of the formulae I and Ia and their racemates ##STR1## in which A is --CH.sub.2 -- or --CH.sub.2 CH.sub.2 --, R.sub.1 is hydrogen or a protective group, R.sub.2 is hydrogen or a protective group or a radical forming a phosphorus-containing nucleotide bridge group and B is a purine or pyrimi ...


2
Karl Heinz Altmann, Ren e Imwinkelried, Albert Eschenmoser: Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates. Ciba Geigy Corporation, Ronald J Campbell, Kevin T Mansfield, March 11, 1997: US05610300 (231 worldwide citation)

Compounds of the formulae I and Ia and their racemates ##STR1## in which A is --CH.sub.2 -- or --CH.sub.2 CH.sub.2 --, R.sub.1 is hydrogen or a protective group, R.sub.2 is hydrogen or a protective group or a radical forming a phosphorus-containing nucleotide bridge group and B is a purine or pyrimi ...


3
Pierre Martin, Karl Heinz Altmann, Phillip Dan Cook, Brett P Monia: Sugar-modified gapped oligonucleotides. ISIS Pharmaceuticals, Novartis, Woodcock Washburn, September 17, 2002: US06451991 (125 worldwide citation)

Oligonucleotides are provided which have increased nuclease resistance, substituent groups for increasing binding affinity to complementary nucleic acid strand, and subsequences of 2′-deoxy-erythro-pentofuranosyl nucleosides that activate RNase H. Such oligonucleotides are useful for diagnostics and ...


4
Marcel Muller, Thomas Geiger, Karl Heinz Altmann, Doriano Fabbro, Nicholas M Dean, Brett Monia, Clarence Frank Bennett: Combination for treatment of proliferative diseases. Novartis Corporation, Henry P Nowak, April 28, 1998: US05744460 (32 worldwide citation)

The invention relates to combinations of PKC-targeted (especially PKC-.alpha.-targeted) deoxyribo- and ribo-oligonucleotides and derivatives thereof with other chemotherapeutic compounds, as well as to pharmaceutical preparations and/or therapies, in relation to disease states which respond to such ...


5
Karl Heinz Altmann, Guido Bold, Giorgio Caravatti, Andreas Flörsheimer: Epothilone derivatives and their use as antitumor agents. Novatis, George R Dohmann, May 14, 2002: US06387927 (29 worldwide citation)

The invention relates to anti-tumour-effective compounds of formula (I), wherein the radicals have the meanings given in the description.


6

7

8
Karl Heinz Altmann, Guido Bold, Pascal Furet, Paul William Manley, Jeanette Marjorie Wood, Stefano Ferrari, Francesco Hofmann, Jürgen Mestan, Andreas Huth, Martin Krüger, Dieter Seidelmann, Andreas Menrad, Martin Haberey, Karl Heinz Thierauch: VEGF receptor tyrosine kinase inhibitors. Novartis, Schering Aktiengesellschaft, Lydia T McNally, George R Dohmann, April 12, 2005: US06878720 (22 worldwide citation)

Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R1 is aryl; R2 is a bicyclic heteroaryl group comprising o ...


9

10
Brett P Monia, Pierre Martin, Karl Heinz Altmann: Antisense oligonucleotide modulation of raf gene expression. Isis Pharmaceuticals, Ciba-Geigy, Law Offices of Jane Massey Licata, July 6, 1999: US05919773 (15 worldwide citation)

Oligonucleotides are provided which are targeted to nucleic acids encoding human c-raf and capable of inhibiting raf expression. The oligonucleotides contain a methoxyethoxy (2'--O--CH.sub.2 CH.sub.2 OCH.sub.3) modification at the 2' position of at least one nucleotide. Methods of inhibiting the exp ...